Genes Webinar | From Genes to Systems: Genetic and Epigenetic Control of the Metastatic Cascade
Genes Webinar | From Genes to Systems: Genetic and Epigenetic Control of the Metastatic Cascade
Part of the Genes Webinar series
22 January 2026
cancer metastasis, genetic alterations, epigenetic reprogramming, tumor heterogeneity, lineage plasticity, metastatic niche formation, dormancy, circulating tumor cells CTCs, immune evasion
Welcome from the Chair
4th Genes Webinar
From Genes to Systems: Genetic and Epigenetic Control of the Metastatic Cascade
This webinar will bring together leading researchers to discuss the genetic and epigenetic mechanisms that regulate cancer metastasis across the full metastatic cascade. Speakers will highlight new insights into chromatin remodeling, non-genetic evolution, tumor cell plasticity, metastatic niche formation, circulating tumor cell biology, and dormancy, as well as multi-omics approaches that reveal how these processes interact at the systems level. The session will consist of five short presentations (15 minutes + 5 minutes for Q&A), emphasizing mechanistic rigor, emerging concepts, and the interplay between tumor-intrinsic programs and the microenvironment. This event accompanies the Special Issue “From Genes to Systems: Genetic and Epigenetic Control of the Metastatic Cascade” in Genes and aims to foster cross-disciplinary dialogue and inspire high-quality contributions to the field.
Date: 22 January 2026
Time: 3:00 PM CET | 9:00 AM EST
Webinar ID: 875 9609 0190
Webinar Secretariat: journal.webinar@mdpi.com
Event Chairs
Dr. Rahrmann is an Assistant Professor and Scientific Advisor for Microscopy and Histology at The Hormel Institute, University of Minnesota. He is also Chair of the Minnesota Metastasis Research Network (MnMet). His laboratory studies the cellular and molecular mechanisms that govern epithelial cell movement, tissue remodeling, and metastatic progression. Dr. Rahrmann is internationally recognized for identifying the Sodium Leak Channel Non-Selective Protein (NALCN) as a key regulator of epithelial cell trafficking in both normal physiology and cancer. His work revealed that NALCN-driven cell dissemination can occur independently of malignant transformation, fundamentally reshaping how metastasis and tissue plasticity are understood. These discoveries have uncovered new principles of cancer biology and highlighted NALCN as both a promising therapeutic target and a potential biomarker for disease progression. Through innovative in vivo models, advanced imaging, and multi-omics approaches, Dr. Rahrmann’s research aims to translate fundamental insights into actionable strategies for cancer diagnosis, prevention, and treatment.
Keynote Speakers
Lewis Katz School of Medicine, Temple University, New York, United States
Dr. Lucia Borriello is an assistant professor at Fox Chase Cancer Center in Philadelphia. The goal of the Borriello Laboratory is lab to understand how the tumor microenvironment regulates the mechanisms of dormancy and awakening of tumor cells in order to identify new therapies targeting dormant tumor cells and preventing metastatic disease. Their mission is to develop novel therapeutic strategies to eradicate dormant tumor cells and combat mortality from metastasis.
Professor William Brackenbury is a Professor in Biomedical Sciences at the Department of Biology at the University of York His lab explores the role of ion channels in disease, focusing on how aberrant ion channel signalling can alter cell behaviour to promote the progression of solid tumours, including breast cancer. We are particularly interested in voltage-gated sodium channels (VGSCs), and their role in regulating membrane electrical activity, adhesion, cellular migration, and invasion. Their current focus is on understanding the mechanisms by which VGSCs regulate the invasion of metastatic breast cancer cells, promoting metastasis.
The University of Chicago, Chicago, United States
Dr. Kaloyan M Tsanov is an Assistant Professor of Medicine and Assistant Professor in the Ben May Department of the Cancer Research Committee on Genetics, Genomics, and Systems Biology at The University of Chicago. The overall goal of his lab research is to elucidate mechanisms that sustain metastatic tumors and to identify related vulnerabilities that can be therapeutically targeted. Their work focuses on pancreatic and gastric cancers, and the three most common sites of metastasis (liver, peritoneum, and lungs) across gastrointestinal malignancies.
Garvan Institute of Medical Research, Sydney, Australia
Dr Heloisa Milioli is a Senior Research Officer in Christine Chaffer’s Laboratory at the Garvan Institute of Medical Research. She integrates molecular biology and computational approaches to investigate the complex mechanisms driving breast cancer development, progression and metastasis. Her research focuses on non-genetic mechanisms governing cell state plasticity and therapy resistance. Her work has been supported by Cancer Institute NSW (2018–2020, Early Career Fellowship), Cancer Council NSW (2023–2026), Tour de Cure (2024) and others. Her research on the context-dependent role of the androgen receptor (AR) in both primary and resistant breast cancer—published in Nature Medicine, Nature Structural & Molecular Biology and MedRxiv—has helped shape ongoing clinical trials (NCT02463032, NCT04947189), underscoring her commitment to improving outcomes for cancer patients in Australia and worldwide.
Dr. Rahrmann is an Assistant Professor and Scientific Advisor for Microscopy and Histology at The Hormel Institute, University of Minnesota. He is also Chair of the Minnesota Metastasis Research Network (MnMet). His laboratory studies the cellular and molecular mechanisms that govern epithelial cell movement, tissue remodeling, and metastatic progression. Dr. Rahrmann is internationally recognized for identifying the Sodium Leak Channel Non-Selective Protein (NALCN) as a key regulator of epithelial cell trafficking in both normal physiology and cancer. His work revealed that NALCN-driven cell dissemination can occur independently of malignant transformation, fundamentally reshaping how metastasis and tissue plasticity are understood. These discoveries have uncovered new principles of cancer biology and highlighted NALCN as both a promising therapeutic target and a potential biomarker for disease progression. Through innovative in vivo models, advanced imaging, and multi-omics approaches, Dr. Rahrmann’s research aims to translate fundamental insights into actionable strategies for cancer diagnosis, prevention, and treatment.
Registration
This is a FREE webinar. After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations with academic institutional email addresses will be prioritized.
Certificates of attendance will be delivered to those who attend the live webinar.
Can’t attend? Register anyway and we’ll let you know when the recording is available to watch.
Program
|
Speaker/Presentation |
Time in EST |
Time in CET |
|
Dr. Eric Rahrmann Chair Introduction. |
9:00 – 9:15 am |
3:00 – 3:15 pm |
|
Dr. Lucia Borriello Chemotherapy Reshapes the Metastatic Niche to Awaken Dormant Tumor Cells |
9:15 – 9:40 am |
3:15 – 3:40 pm |
|
Prof. William Brackenbury Bioelectrical control of breast cancer metastasis by voltage-gated sodium channels |
9:40 – 10:05 am |
3:40 – 4:05 pm |
|
Dr. Kaloyan M. Tsanov Organ-specific Effects of SMAD4 in Metastatic Pancreatic Cancer |
10:05 – 10:30 am |
4:05 – 4:30 pm |
|
Dr. Heloisa Z. Milioli Androgen Receptor (AR)-mediated Epigenetic Regulation of Cell States in Triple-negative Breast Cancer |
10:30 – 10:55 am |
4:30 – 4:55 pm |
|
Dr. Eric Rahrmann Bioelectric Control of Metastasis: The Emerging Role of NALCN |
10:55 - 11:20 am |
4:55 - 5:20 pm |
|
Q&A Session |
11:20 – 11:35 am |
5:20 – 5:35 pm |
|
Closing of Webinar Dr. Eric Rahrmann (Chair) |
11:35 – 11:40 am |
5:35 – 5:40 pm |
Relevant Special Issue
Sponsors and Partners
Organizers
Event Organizers
MDPI
MDPI
A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. Based in Basel, Switzerland, MDPI has the mission to foster open scientific exchange in all forms, across all disciplines.
Our 493 diverse and open access journals, including 484 peer-reviewed journals and 9 conference journals, are supported by more than 295,000 academic experts who share our mission, values, and commitment to providing high-quality service for our authors. We serve scholars from around the world to ensure the latest research is freely available and all content is distributed under a Creative Commons Attribution License (CC BY).
MDPI's portfolio comprises at least 298 journals with impact factors, 64% of which are ranked in the top 2 quartiles of their respective fields. To view the current impact factors for MDPI journals (according to the Journal Citation Reports), please visit our yearly announcement page here.
journal.webinar@mdpi.com
Genes Journal
MDPI
Genes is a peer-reviewed, open access journal of genetics and genomics published monthly online by MDPI. The Spanish Society for Nitrogen Fixation (SEFIN) is affiliated with Genes and its members receive discounts on the article processing charges.
genes@mdpi.com
